Answers are grounded in this paper and cite their sources.
Evaluates cfDNA and FFPE DNA analysis for predicting outcomes in lung cancer, suggesting new diagnostic approaches.
Cancer burden is a globally growing problem. Early diagnosis and targeted treatment decrease patients' death rate, pain, and treatment expenses. Liquid biopsy can be used for early cancer detection, treatment selection, and progression and treatment response monitoring. We evaluated the performance of circulating cell-free DNA (cfDNA) and formalin-fixed paraffin-embedded (FFPE) tissue DNA analyses using a commonly employed targeted therapeutic pathway in predicting the outcomes of patients with lung cancer, a common cancer with a generally poor prognosis.
No takes yet. Share an insight, caveat, or question.
Tamm et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: